ライフサイエンスコーパス: human monoclonal antibody

1 ein G in complex with a broadly neutralizing human monoclonal antibody.

2 CSPG4-specific chimeric, humanized, or fully human monoclonal antibody.

3 the epitopes of several broadly neutralizing human monoclonal antibodies.

4 ell as the potency of convalescent plasma or human monoclonal antibodies.

5 antibody binding and apply this method to 10 human monoclonal antibodies.

6 ics comparable to those of other therapeutic human monoclonal antibodies.

7 epitope sites targeted by virus neutralising human monoclonal antibodies.

8 he isolation and characterization of a fully human monoclonal antibody (1C1) that selectively binds b

9 om the polyreactive and broadly neutralizing human monoclonal antibody 2F5 was targeted into the mous

10 The broadly neutralizing human monoclonal antibody 2F5 was used to select for vir

11 with the corresponding broadly neutralizing human monoclonal antibody 2F5, provides a target for str

12 rystal structure of the broadly neutralizing human monoclonal antibody 3G12 bound to the RSV G centra

13 lasmablast enrichment technique to isolate a human monoclonal antibody, 46B8 that neutralizes all IBV

14 ed gp41-specific cross-reactive neutralizing human monoclonal antibodies, 4E10 and 2F5, target linear

15 r actions of two rare, broadly neutralizing, human monoclonal antibodies, 4E10 and 2F5, which target

16 Here we show that the DENV-specific human monoclonal antibody 5J7 is exceptionally potent, n

17 We isolated human monoclonal antibody 5J8, which neutralized a broad

18 that the hemagglutinin (HA) stalk-targeting human monoclonal antibody 81.39a effectively neutralized

19 d from VZV-infected cells, in complex with a human monoclonal antibody, 93k.

20 ated a large panel of orthopoxvirus-specific human monoclonal antibodies (Abs) from immune subjects t

21 A combination of human monoclonal antibodies, actoxumab and bezlotoxumab,

22 Neutralizing human monoclonal antibodies against alpha-toxin (AT) and

23 -controlled study of two neutralizing, fully human monoclonal antibodies against C. difficile toxins

24 , we identified a panel of macropinocytosing human monoclonal antibodies against CD46, a negative reg

25 We show that human monoclonal antibodies against NA induced by vaccin

26 We have previously identified neutralizing human monoclonal antibodies against Nipah virus (NiV) an

27 Production of human monoclonal antibodies against Stx, which are highl

28 utaneous and intravenous evinacumab, a fully human monoclonal antibody against angiopoietin-like 3, a

29 We also tested the effect of a human monoclonal antibody against ANGPTL4 on lipid level

30 f pamrevlumab (FG-3019), a fully recombinant human monoclonal antibody against CTGF, in idiopathic pu

31 We aimed to compare panitumumab, a fully human monoclonal antibody against EGFR, plus radiotherap

32 Burosumab, a human monoclonal antibody against FGF23, improves phosph

33 in D, versus switching to burosumab, a fully human monoclonal antibody against FGF23, in paediatric X

34 Then we report the identification of HS20, a human monoclonal antibody against GPC3, which preferenti

35 Secukinumab, a fully human monoclonal antibody against IL-17A, shows signific

36 hn's disease, the efficacy of ustekinumab, a human monoclonal antibody against interleukin-12 and int

37 sed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 recepto

38 the development of a highly effective fully human monoclonal antibody against Jagged1 (clone 15D11).

39 Opicinumab is a human monoclonal antibody against LINGO-1, an inhibitor

40 We assessed the effects of AMG 145, a human monoclonal antibody against PCSK9, in patients wit

41 Evolocumab, a fully human monoclonal antibody against proprotein convertase

42 AMG 145, a fully human monoclonal antibody against proprotein convertase

43 randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of

44 vestigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of

45 vestigated the ability of denosumab, a fully human monoclonal antibody against receptor activator of

46 We generated a human monoclonal antibody against scavenger receptor cla

47 5C12 HuMAb is a human monoclonal antibody against the A subunit of Shiga

48 the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for

49 the efficacy and safety of erenumab, a fully human monoclonal antibody against the CGRP receptor, in

50 Dupilumab, a VelocImmune-derived human monoclonal antibody against the interleukin (IL) 4

51 Ustekinumab is a fully human monoclonal antibody against the p40 subunit of int

52 Lexatumumab is an agonistic, fully human monoclonal antibody against tumor necrosis factor-

53 Ganitumab is a fully human monoclonal antibody against type-1 insulin-like gr

54 Evolocumab is a fully human, monoclonal antibody against PCSK9 that reduces lo

55 A ligand-mimetic human monoclonal antibody AL-57 (activated LFA-1 clone 5

56 oires offers a novel route to discover fully human monoclonal antibodies and identify antigens of pot

57 of nAbs and suggest a cooperative effect of human monoclonal antibodies and IFITMs for antibody-medi

58 sensitivity to neutralizing patient IgG and human monoclonal antibodies AR3A and AR4A and (ii) incre

59 upport further development of m336 and other human monoclonal antibodies as potential therapeutics fo

60 bust system for the discovery of therapeutic human monoclonal antibodies; as a surrogate readout of t

61 The human monoclonal antibody b12 recognizes a conserved epi

62 Bezlotoxumab, a human monoclonal antibody, binds to C. difficile toxin B

63 aracterization of typhoid toxin-neutralizing human monoclonal antibodies by immunizing genetically en

64 We have previously described a human monoclonal antibody called KM33 that blocks these

65 Selection of human monoclonal antibodies can identify immunodominant

66 We describe a human monoclonal antibody, CH65, obtained by isolating r

67 port the isolation and characterization of a human monoclonal antibody CR8020 with broad neutralizing

68 Here, we report human monoclonal antibodies, CR8033, CR8071, and CR9114,

69 The human monoclonal antibody, D5, binds to this target and

70 s with a potency that rivals that of several human monoclonal antibodies, demonstrating that computat

71 HLA class I-specific human monoclonal antibodies derived from women sensitize

72 Fully human monoclonal antibodies directed against the binding

73 Evolocumab, a fully human monoclonal antibody directed against proprotein co

74 We assessed ustekinumab, a human monoclonal antibody directed against these cytokin

75 S for simultaneous detection of the residual human monoclonal antibody drug and endogenous human IgG

76 Studies using isolation of human monoclonal antibodies followed by structural and f

77 Among a panel of 18 dengue virus-reactive human monoclonal antibodies, four groups of antibodies w

78 isplay to produce a panel of chimeric rabbit/human monoclonal antibody fragments (both Fab and scFv)

79 Here, we isolated human monoclonal antibodies from B cells of four survivo

80 Interestingly, individual human monoclonal antibodies from both healthy and inflam

81 , we isolated a panel of dengue prM-specific human monoclonal antibodies from individuals after infec

82 We derived human monoclonal antibodies from persons who received th

83 agents against ZIKV, we isolated a panel of human monoclonal antibodies from subjects that were prev

84 Further, by using TG2-specific human monoclonal antibodies generated from intestinal pl

85 The human monoclonal antibody HC-1 recognizes a conformation

86 n of the Fab fragment of an affinity-matured human monoclonal antibody (HC84.26.5D) that recognizes t

87 Recombinant human monoclonal antibodies (hmAb) against gliadin are p

88 trated that DENV serotype 2 (DENV2)-specific human monoclonal antibody (HMAb) 2D22 is therapeutic in

89 Human monoclonal antibody (hMAb) targeting the hemagglut

90 ally characterized for binding to a panel of human monoclonal antibodies (HMAbs) and the coreceptor C

91 Five human monoclonal antibodies (HMAbs) are described that c

92 In the current study, we obtained human monoclonal antibodies (hMAbs) directly from antibo

93 roduction and analysis of HIV-1 Env-specific human monoclonal antibodies (hMAbs) isolated from vaccin

94 nistic studies with anti-dengue virus (DENV) human monoclonal antibodies (hMAbs) provide a rational a

95 Highly neutralizing type-specific human monoclonal antibodies (hmAbs) target conformation-

96 tro against a panel of 12 well-characterized human monoclonal antibodies (HMAbs) targeting diverse E1

97 Epitope mapping of human monoclonal antibodies (HMAbs) that bind to an adja

98 erplay between these antibodies, we isolated human monoclonal antibodies (HMAbs) to aa 412 to 423, de

99 omplementary strategy is to use neutralizing human monoclonal antibodies (HMAbs) to prevent acute inf

100 Human monoclonal antibodies (HMAbs) with neutralizing ca

101 lobal E2 alanine scanning with a panel of 16 human monoclonal antibodies (hmAbs), resulting in an unp

102 ation by chronic-phase patient sera and lead human monoclonal antibodies (HMAbs).

103 tocol for the production of antigen-specific human monoclonal antibodies (hmAbs).

104 d binding affinity of a panel of anti-HCV E2 human monoclonal antibodies (HMAbs).

105 We investigated the efficacy of specific human monoclonal antibodies (HuMab) and alpaca polyclona

106 igational product containing a mixture of 26 human monoclonal antibodies (HuMAbs) against mature viri

107 ed with OspA from B. burgdorferi to generate human monoclonal antibodies (HuMabs) against OspA.

108 P-19) hypervariable region 1 (HVR1)-specific human monoclonal antibodies (huMAbs) are protective thro

109 pursue this treatment modality, we developed human monoclonal antibodies (HuMAbs) directed against th

110 We have previously shown that Stx2-specific human monoclonal antibodies (HuMAbs) protect mice and pi

111 fragments of antigen binding (Fabs) from two human monoclonal antibodies, IgG-94 and IgG-RC, isolated

112 uid-liquid phase separation in a solution of human monoclonal antibody, IgG2, and the effects of huma

113 e expression of an EGFP-labeled single-chain human monoclonal antibody, IK17, which binds to MDA-LDL,

114 cacy, and tolerability of bimagrumab-a fully human monoclonal antibody-in individuals with inclusion

115 e binding of the NA of A(H3N2) virus by some human monoclonal antibodies, including those that have b

116 e the efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patien

117 Characterization of human monoclonal antibodies is providing considerable in

118 The isolation of human monoclonal antibodies is providing important insig

119 We describe three human monoclonal antibodies isolated from an H3N2-infect

120 CR4354, a human monoclonal antibody isolated from a patient, neutr

121 d to the Fab fragment of 1G2, a neutralizing human monoclonal antibody isolated from a seropositive s

122 n addition, the technological convergence of human monoclonal antibody isolation, structural biology,

123 Mapping of human monoclonal antibodies led to the discovery of six

124 AGMs showed that the therapeutic window for human monoclonal antibody m102.4, previously shown to re

125 Here we report a human monoclonal antibody, m826, that binds to H7 hemagg

126 Additionally, chimeric and human monoclonal antibodies (mAb) against the EBOV GP ha

127 We solved the crystal structure of human monoclonal antibody (MAb) 2158, which targets a co

128 The human monoclonal antibody (MAb) A32 is a nonneutralizing

129 Competitive binding of the human monoclonal antibody (mAb) LE2E9 revealed overlappi

130 including an A32-like epitope, recognized by human monoclonal antibody (MAb) N60-i3, and a hybrid A32

131 Ustekinumab is a fully human monoclonal antibody (mAb) that binds specifically

132 first to enter the clinic, ustekinumab, is a human monoclonal antibody (mAb) that binds to the p40 su

133 ve at blocking opsonic killing mediated by a human monoclonal antibody (mAb) to native PNAG than it w

134 Here, we report that one human monoclonal antibody (MAb), 53C10, isolated from tr

135 primates with a cross-reactive, neutralizing human monoclonal antibody (mAb), m102.4, targeting the G

136 evolution, and structure of a broad-spectrum human monoclonal antibody (mAb), MEDI8852, effectively r

137 We isolated a human monoclonal antibody (mAb), ZKA190, that potently c

138 only one well-studied, strongly neutralizing human monoclonal antibody (mAb).

139 Two human monoclonal antibodies, mAb100 and mAb114, in combi

140 Two human monoclonal antibodies (MAbs) (2F5 and 4E10) agains

141 The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both ta

142 We isolated a large panel of human monoclonal antibodies (mAbs) against BDBV glycopro

143 We screened a panel of mouse and human monoclonal antibodies (MAbs) against chikungunya v

144 ere, we report the first naturally occurring human monoclonal antibodies (mAbs) against HeV receptor

145 We isolated a panel of human monoclonal antibodies (mAbs) against PfRH5 from pe

146 virus-like particles (VLPs) to isolate seven human monoclonal antibodies (MAbs) against the CHIKV env

147 dy discovery platform to isolate hundreds of human monoclonal antibodies (mAbs) against the SARS-CoV-

148 We tested whether human monoclonal antibodies (MAbs) against the three maj

149 We previously generated a panel of human monoclonal antibodies (mAbs) against Zika virus (Z

150 t into dengue immunity, we characterized 145 human monoclonal antibodies (mAbs) and identified a prev

151 1 due to modest potency and breadth of early human monoclonal antibodies (MAbs) and perceived insurmo

152 n-specific sorting, we isolated Env-specific human monoclonal antibodies (MAbs) and studied the clona

153 he genes encoding broadly HIV-1-neutralizing human monoclonal antibodies (MAbs) are highly divergent

154 Antiviral human monoclonal antibodies (mAbs) are promising candida

155 To guide vaccine design, we assessed whether human monoclonal antibodies (MAbs) b12 and b6 against th

156 influenza virus hemagglutinin (HA)-reactive human monoclonal antibodies (MAbs) by hybridoma technolo

157 We characterized human monoclonal antibodies (MAbs) cloned from influenza

158 RECENT FINDINGS: Human monoclonal antibodies (mAbs) derived from rheumati

159 Fully human monoclonal antibodies (mAbs) derived from transgen

160 Among 598 human monoclonal antibodies (mAbs) from 10 COVID-19 pati

161 We report here the identification of human monoclonal antibodies (MAbs) from a large nonimmun

162 We identified panels of fully human monoclonal antibodies (mAbs) from large phage-disp

163 We isolated 35 human monoclonal antibodies (mAbs) from two H7N9 survivo

164 Although highly inhibitory murine and human monoclonal antibodies (mAbs) have been generated,

165 Here, we characterize human monoclonal antibodies (mAbs) isolated from a survi

166 tion of a large panel of naturally occurring human monoclonal antibodies (MAbs) obtained from subject

167 Human monoclonal antibodies (MAbs) specific for HIV-2 V3

168 Here we have cloned 113 human monoclonal antibodies (mAbs) specific for LASV gly

169 e human B-cell response to IsdA, we isolated human monoclonal antibodies (mAbs) specific to the surfa

170 Discovering potent human monoclonal antibodies (mAbs) targeting the Plasmod

171 For Pseudomonas aeruginosa, human monoclonal antibodies (mAbs) targeting the Psl bio

172 Here, we describe human monoclonal antibodies (mAbs) that bind to and neut

173 d from sorted single ASCs to produce over 50 human monoclonal antibodies (mAbs) that bound to the thr

174 We isolated and characterized human monoclonal antibodies (mAbs) that neutralize CHIKV

175 We identified human monoclonal antibodies (mAbs) that neutralize genet

176 Two human monoclonal antibodies (MAbs) that neutralized DENV

177 ated from a single donor 13 new neutralizing human monoclonal antibodies (mAbs) that recognize the RS

178 Here, we isolated and characterized human monoclonal antibodies (mAbs) that target IBV NA fr

179 Using a panel of human monoclonal antibodies (mAbs) to DENV, we showed th

180 We report 3 LukAB-specific human monoclonal antibodies (mAbs) with distinct mechani

181 d neutralization properties of 15 anti-HIV-2 human monoclonal antibodies (MAbs), 14 of which were new

182 iously characterized a panel of neutralizing human monoclonal antibodies (MAbs), but the majority of

183 Several neutralizing human monoclonal antibodies (mAbs), including m336, a ge

184 We identified three human monoclonal antibodies (MAbs), m336, m337, and m338

185 ultaneous quantitation of two coadministered human monoclonal antibodies (mAbs), mAb-A and mAb-B of I

186 Using fully human monoclonal antibodies (MAbs), we now have shown th

187 for neutralizing antibodies in studies using human monoclonal antibodies (MAbs).

188 Human monoclonal antibodies may be a useful adjunct to f

189 ing activity of both convalescent plasma and human monoclonal antibodies measured using each virus co

190 We have developed a fully human monoclonal antibody, MEDI-575, that selectively bi

191 We show that the human monoclonal antibody, MEDI1912, selected against ne

192 rted the isolation and characterization of 2 human monoclonal antibodies neutralizing CHIKV in vitro:

193 s a neutralizing anti-interleukin-13 (IL-13) human monoclonal antibody obtained from a phage display

194 robust SCID mouse-based method for isolating human monoclonal antibodies of desired specificity from

195 The human monoclonal antibody opicinumab (BIIB033, anti-LING

196 argeted liposomal nanoprobe by conjugating a human monoclonal antibody, PGN635 that specifically targ

197 ecognized by a recently discovered family of human monoclonal antibodies (PGT151-PGT158).

198 We found that human monoclonal antibodies recognized the Sa antigenic

199 a single-chain variable fragment of the 17b human monoclonal antibody recognizing a highly conserved

200 lly, neutralizing M-CSF activity via a novel human monoclonal antibody reduced the CD14(+)CD16(+) mon

201 Here, we analyzed the human monoclonal antibody response to acute ZIKV infecti

202 es and provide a better understanding of the human monoclonal antibody response to influenza in the c

203 -B12, and -B35 expression on platelets using human monoclonal antibodies specific for these antigens.

204 safety of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-ce

205 Golimumab is a human monoclonal antibody specific for tumor necrosis fa

206 Ipilimumab, a human monoclonal antibody targeted against cytotoxic T-l

207 . vivax in vitro against invasion inhibitory human monoclonal antibodies targeting a conserved bindin

208 Fully human monoclonal antibodies targeting CTLA-4 have been s

209 The efficacy of TCN-032, a human monoclonal antibody targeting a conserved epitope

210 Ofatumumab (HuMax-CD20) is a human monoclonal antibody targeting a distinct small-loo

211 Daratumumab is a human monoclonal antibody targeting CD38, an antigen uni

212 Daratumumab (DARA), a human monoclonal antibody targeting CD38, has significan

213 Daratumumab, a human monoclonal antibody targeting CD38, is approved as

214 Panitumumab, a fully human monoclonal antibody targeting the epidermal growth

215 Panitumumab, a fully human monoclonal antibody targeting the epidermal growth

216 Dupilumab, a fully human monoclonal antibody targeting the interleukin-4 re

217 also make possible the rapid development of human monoclonal antibodies that could become a potent i

218 Here we show that a combination of human monoclonal antibodies that cross-react with the gl

219 Here, we describe a set of human monoclonal antibodies that define what is, to the

220 Many human monoclonal antibodies that neutralize multiple cla

221 Human monoclonal antibodies that potently and broadly ne

222 Here we report the isolation of human monoclonal antibodies that recognize erythrocytes

223 Here we analyse a large panel of human monoclonal antibodies that target the spike (S) gl

224 Here, we exploit 3F6-hIgG1, a human monoclonal antibody that binds and neutralizes the

225 Ipilimumab is a fully human monoclonal antibody that binds cytotoxic T-lymphoc

226 Dupilumab, a fully human monoclonal antibody that binds IL-4Ralpha and inhi

227 Conatumumab is a fully human monoclonal antibody that binds to and activates hu

228 PF-00547659 is a fully human monoclonal antibody that binds to human mucosal ad

229 Panitumumab, a human monoclonal antibody that binds to the epidermal gr

230 Ustekinumab is a human monoclonal antibody that binds to the shared p40 s

231 Denosumab is a fully human monoclonal antibody that binds to, and inhibits, t

232 Adalimumab is a fully human monoclonal antibody that binds tumor necrosis fact

233 ment after treatment with dupilumab, a fully-human monoclonal antibody that blocks both pathways.

234 Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lympho

235 Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and

236 Bimagrumab is a fully human monoclonal antibody that blocks the activin type I

237 erm infants of 1 or 2 doses of suptavumab, a human monoclonal antibody that can bind and block a cons

238 This identified a broadly neutralizing human monoclonal antibody that inhibited invasion of all

239 Osocimab is a long-acting, fully human monoclonal antibody that inhibits factor XIa.

240 Ustekinumab is a human monoclonal antibody that inhibits receptor-binding

241 Dupilumab is a fully human monoclonal antibody that inhibits signalling of in

242 We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin g

243 Canakinumab, a human monoclonal antibody that neutralizes interleukin-1

244 This drug, belimumab (Benlysta), is a human monoclonal antibody that neutralizes the B-cell su

245 ule (V1V2ZM109-1FD6) in complex with 830A, a human monoclonal antibody that recognizes a V1V2 epitope

246 Sirukumab, a human monoclonal antibody that selectively binds to the

247 BACKGROUND & AIMS: MEDI2070 is a human monoclonal antibody that selectively inhibits inte

248 re we report the generation of aducanumab, a human monoclonal antibody that selectively targets aggre

249 Rilotumumab is a fully human monoclonal antibody that selectively targets the l

250 Guselkumab, a human monoclonal antibody that specifically inhibits IL-

251 MEDI4893 is a neutralizing human monoclonal antibody that targets alpha-toxin (AT)

252 PET/NIRF) imaging agents, using 5B1, a fully human monoclonal antibody that targets CA19.9, a well-es

253 Daratumumab, a human monoclonal antibody that targets CD38, depletes pl

254 Panitumumab is a fully human monoclonal antibody that targets EGFR.

255 vascular risk indicates that canakinumab, a human monoclonal antibody that targets IL-1beta, markedl

256 5B1 is a fully human, monoclonal antibody that has shown promise for th

257 Rilotumumab is a fully human, monoclonal antibody that neutralises HGF.

258 model in humanized mice and used it to test human monoclonal antibody therapy.

259 ires can be mined for the discovery of fully human monoclonal antibodies to B-CLL cell-surface antige

260 We generated a total of 63 new human monoclonal antibodies to compare the B-cell respon

261 In this study, we have generated a panel of human monoclonal antibodies to dengue virus.

262 We evaluated the therapeutic activity of human monoclonal antibodies to DENV EDE for their abilit

263 readth of the recently isolated neutralizing human monoclonal antibodies to HIV-1 have stimulated int

264 We identify human monoclonal antibodies to O-antigens that are highl

265 blished phase I and II trials with two fully human monoclonal antibodies to PCSK9 have provided compr

266 o review the phase 1 and 2 trials with fully human monoclonal antibodies to proprotein convertase sub

267 CBH-2 is a neutralizing human monoclonal antibody to a domain B epitope that is

268 ite the clinical validation of this model, a human monoclonal antibody to CA19.9 (a highly visible bu

269 In addition, treatment with a human monoclonal antibody to HCMV glycoprotein B rescues

270 maturation, and characterization of a fully human monoclonal antibody to human NKG2D.

271 We have isolated a human monoclonal antibody to IL-17A (CAT-2200) that can

272 Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein convertas

273 In phase 1 studies, a human monoclonal antibody to PCSK9, AMG145, was well tol

274 assessed the effects of evolocumab, a fully human monoclonal antibody to PCSK9, on Lp(a), the relati

275 AMG 145, a fully human monoclonal antibody to PCSK9, prevents PCSK9/LDL-R

276 In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels

277 SAR236553 is a fully human monoclonal antibody to PCSK9.

278 A second monoclonal antibody [PRM1 (human monoclonal antibody to PR)], which recognizes part

279 Evolocumab, a fully human monoclonal antibody to proprotein convertase subti

280 ts were passively immunized with AVP-21D9, a human monoclonal antibody to protective antigen (PA), at

281 Denosumab is an investigational fully human monoclonal antibody to receptor activator of nucle

282 Denosumab, a fully human monoclonal antibody to receptor activator of nucle

283 ty of dupilumab (SAR231893/REGN668), a fully human monoclonal antibody to the alpha subunit of the in

284 Denosumab is a fully human monoclonal antibody to the receptor activator of n

285 Subcutaneous golimumab, a fully human monoclonal antibody to tumor necrosis factor-alpha

286 activity as an immunogen, we generated fully human monoclonal antibodies using the XenoMouse(TM) plat

287 The fully human monoclonal antibody ustekinumab is an efficacious

288 t of cell culture-grown HCV infectivity by a human monoclonal antibody was also observed.

289 of several neutralizing and nonneutralizing human monoclonal antibodies were also determined, which

290 tralize inhibitory RGMa, clinically relevant human monoclonal antibodies were systemically administer

291 Cross-reactivity was studied using a human monoclonal antibody which inhibits allergic patien

292 sma cells, we generated several HPV-specific human monoclonal antibodies, which exhibited a high degr

293 ZIKV nonstructural protein 1 (NS1)-specific human monoclonal antibody, which we used to develop an N

294 lated and characterized two protective fully human monoclonal antibodies with specificity for protect

295 ration-dependent self-interactions for three human monoclonal antibodies with unique solution behavio

296 Here we present a broadly neutralizing human monoclonal antibody with an unusual binding modali

297 Here, we show that a human monoclonal antibody with pan-amyloid-binding activ

298 and identified a high affinity, allosteric, human monoclonal antibody, XMetA, which mimicked the glu

299 h Fab fragments of the potently neutralizing human monoclonal antibody ZIKV-195.

300 ent of a highly therapeutic and neutralizing human monoclonal antibody, ZIKV-117.